Amgen and Illumina Enter Agreement to Develop Oncology Companion Diagnostic Test

20-01-2014 Business Wire HealthComments (0)

AmgenBiotechnologyIllumina

Illumina, Inc. (NASDAQ:ILMN) today announced it has entered into an agreement with Amgen Inc. to develop and commercialize a multigene, NGS-based test as a companion diagnostic for Vectibix (panitumumab), a fully human anti-EGFR monoclonal antibody therapeutic for the treatment of metastatic colorectal cancer approved in the US and EU. Under the terms of the collaboration, premarket approval of the test by the US Food and Drug Administration (FDA) and other regulator

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top